NN-9931 is a recombinant peptide commercialized by Novo Nordisk, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Dementia risk factors have greater impact on minority ethnic groups
Factors that increase the risk of dementia have a greater impact on risk for people in minority ethnic groups, finds a new study led by